F-group (family)
206.1.1.20 PK_Tyr_Ser-Thr
Ligands and drugs
7,799
Member domains
3,908
with ligand contacts (≤ 4 Å)
50.1% of members
3,530
with DrugDomain annotations
45.3% of members
1,682
with a DrugBank compound
21.6% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 206.1.1.20 belongs to X-group 206 Protein kinase/SAICAR synthase/ATP-grasp, which binds 10.2 ligand superclasses per 20 proteins, broader than 96% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB12010 | — | Fostamatinib | 80 |
| DB03909 | ACP | Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate | 60 |
| DB00619 | STI | Imatinib | 44 |
| DB16833 | ADP | Adenosine disphosphate | 42 |
| DB02010 | STU | Staurosporine | 41 |
| DB01254 | 1N1 | Dasatinib | 39 |
| DB08901 | 0LI | Ponatinib | 34 |
| DB18051 | LDN | LDN-193189 | 29 |
| DB00171 | ATP | ATP | 20 |
| DB09330 | YY3 | Osimertinib | 18 |
| DB09459 | TLA | L-tartaric acid | 17 |
| DB15035 | — | — | 17 |
| DB02930 | AGS | Adenosine 5'-[gamma-thio]triphosphate | 14 |
| DB06616 | DB8 | Bosutinib | 14 |
| DB08877 | RXT | Ruxolitinib | 14 |
| DB00398 | BAX | Sorafenib | 13 |
| DB08896 | — | — | 13 |
| DB15822 | — | Pralsetinib | 13 |
| DB08912 | P06 | Dabrafenib | 12 |
| DB09079 | — | Nintedanib | 12 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| MGmetal | MAGNESIUM ION | 258 |
| CL | CHLORIDE ION | 235 |
| ANP | PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER | 173 |
| LU8 | 4-methyl-3-[4-(1-methylpiperidin-4-yl)phenyl]-5-(3,4,5-trimethoxyphenyl)pyridine | 90 |
| ACP | PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER | 60 |
| CAmetal | CALCIUM ION | 52 |
| STI | 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE | 45 |
| STU | STAUROSPORINE | 44 |
| ADP | ADENOSINE-5'-DIPHOSPHATE | 43 |
| NAmetal | SODIUM ION | 31 |
| IOD | IODIDE ION | 30 |
| LDN | 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline | 29 |
| 1N1 | N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE | 28 |
| 0LI | 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide | 26 |
| ATP | ADENOSINE-5'-TRIPHOSPHATE | 25 |
| PHU | 1-phenylurea | 19 |
| VNS | (2R)-2-(5-fluoro-2-hydroxyphenyl)-2-{6-[4-(1-methylpiperidin-4-yl)phenyl]-1-oxo-1,3-dihydro-2H-isoindol-2-yl}-N-(1,3-thiazol-2-yl)acetamide | 19 |
| YY3 | N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide | 19 |
| TZ0 | 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one | 18 |
| JBJ | (2R)-2-(5-fluoro-2-hydroxyphenyl)-2-{1-oxo-6-[4-(piperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindol-2-yl}-N-(1,3-thiazol-2-yl)acetamide | 17 |